Fischer, KE. A systematic review of coverage decision-making on health technologies-evidence from the real world. Health Policy. 2012;107:218–230.
Guindo, LA, Wagner, M, Baltussen, R, et al.
From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking. Cost Eff Resour Alloc. 2012;10:9.
Henshall, C, Schuller, T, Mardhani-Bayne, L. Using health technology assessment to support optimal use of technologies in current practice: The challenge of “disinvestment”. Int J Technol Assess Health Care. 2012;28:203–210.
Tromp, N, Baltussen, R. Mapping of multiple criteria for priority setting of health interventions: An aid for decision makers. BMC Health Serv Res. 2012;12:454.
Tony, M, Wagner, M, Khoury, H, et al.
Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): Field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. BMC Health Serv Res. 2011;11:329.
Harris, AH, Hill, SR, Chin, G, Li, JJ, Walkom, E. The role of value for money in public insurance coverage decisions for drugs in Australia: A retrospective analysis 1994–2004. Med Decis Making. 2008;28: 713–722.
Ottersen, TNO, Chitah, BM, Cookson, R, Daniels, N, et al.
Making fair choices on the path to universal health coverage. Final report of the WHO Consultative Group on Equity and Universal Health Coverage. Geneva: WHO; 2014.
Faunce, TA. Challenges for Australia's bio/nanopharma policies: Trade deals, public goods and reference pricing in sustainable industrial renewal. Aust New Zealand Health Policy. 2007;4:9.
Daniels, N. Accountability for reasonableness. BMJ. 2000;321:1300–1301.
Alonso-Coello, P, Oxman, AD, Moberg, J, et al.
GRADE Evidence to Decision (EtD) frameworks: A systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089.
Alonso-Coello, P, Schünemann, HJ, Moberg, J, et al.
GRADE Evidence to Decision (EtD) frameworks: A systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.
Treweek, S, Oxman, AD, Alderson, P, et al.
Developing and evaluating communication strategies to support informed decisions and practice based on evidence (DECIDE): Protocol and preliminary results. Implement Sci. 2013;8:6.
Schünemann, HJ, Mustafa, R, Brozek, J, et al.
GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol. 2016;76:89–98.
Claxton, K, Martin, S, Soares, M, et al.
Methods for the estimation of the National Institute for Health and Care Excellence cost effectiveness threshold. Health Technol Assess. 2013;19:1–503.
Rocchi, A, Menon, D, Verma, S, Miller, E. The role of economic evidence in Canadian oncology reimbursement decision-making: To lambda and beyond. Value Health. 2008;11:771–783.
Drummond, MF, Schwartz, JS, Jonsson, B, et al.
Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24:244-258; discussion 362–368.
Levin, L, Goeree, R, Levine, M, et al.
Coverage with evidence development: The Ontario experience. Int J Technol Assess Health Care. 2011;27:159–168.
Hutton, J, Trueman, P, Henshall, C. Coverage with evidence development: An examination of conceptual and policy issues. Int J Technol Assess Health Care. 2007;23:425–432.
Ilic, D, Neuberger, MM, Djulbegovic, M, Dahm, P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1:CD004720.
Heijnsdijk, EA, Wever, EM, Auvinen, A, et al.
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 367;367:595–605.
Djulbegovic, M, Beyth, RJ, Neuberger, MM, et al.
Screening for prostate cancer: Systematic review and meta-analysis of randomised controlled trials. BMJ. 2010;341:c4543.
de Bekker-Grob, EW, Rose, JM, Donkers, B, et al.
Men's preferences for prostate cancer screening: A discrete choice experiment. Br J Cancer. 2013;108:533–541.
Drummond, M. Twenty years of using economic evaluations for drug reimbursement decisions: What has been achieved?
J Health Polit Policy Law. 2013;38:1081–1102.
Dakin, H, Devlin, N, Feng, Y, Rice, N, O'Neill, P, Parkin, D. The influence of cost-effectiveness and other factors on nice decisions. Health Econ. 2014 [Epub ahead of print].
Jefferson, T, Demicheli, V. Quality of economic evaluations in health care. BMJ. 2002;324:313–314.
Brunetti, M, Shemilt, I, Pregno, S, et al.
GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol. 2013;66:140–150.
Garrison, LP Jr, Towse, A, Briggs, A, et al.
Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16:703–719.
Neumann, I, Brignardello-Petersen, R, Wiercioch, W, et al.
The GRADE evidence-to-decision framework: A report of its testing and application in 15 international guideline panels. Implement Sci. 2016;11:93.
Gonzalez-Lorenzo, M, Piatti, A, Coppola, L, et al.
Conceptual frameworks and key dimensions to support coverage decisions for vaccines. Vaccine. 2015;33:1206–1217.